Mexican scorpion research could yield cancer and Parkinson's disease drugs

By Gareth Macdonald contact

- Last updated on GMT

Mexican scorpion research could produce new cancer and Parkinson's disease drugs
Mexican scorpion research could produce new cancer and Parkinson's disease drugs

Related tags: Protein

Proteins found in scorpion venom could yield cancer and Parkinson’s disease drugs say Mexican researchers.

The University of Colima (UCOL) team identified proteins in the venom of the Centruroides tecomanus​ scorpion that can kill cancerous cells by binding and blocking ion channels expressed on the surface of tumours.

Lead researcher Laura Leticia Valdez Velazquez told Biopharma-Reporter.com “you could use these peptides as medicines​” explaining that because the proteins only bind ion channels expressed by cancerous tissue, healthy cells will not be affected.

Valdez and her colleagues from the Institute of Biotechnology of the National Autonomous University of Mexico (UNAM) are also researching scorpion venom proteins as potential treatments for Parkinson’s disease.

Rat studies suggest several of the 100 protein molecules identified in scorpion venom bind receptors on dopaminergic neurons and increase dopamine release.

This interaction could eventually be used to moderate levels of the neurotransmitter and treat the degenerative brain disease, however, as Valdez colourfully points out, the research is still at an early stage.

To treat humans would require finding an appropriate delivery route that allows the peptide to pass the blood brain barrier and reach the brain without having to drill a hole in the skull​” she said.

Valdez said the researchers are now looking for partners interested in developing drugs from the venom proteins and suggested that connections made during her participation in the EU 7th Framework programme​ could prove useful.

Scorpion central

Mexico is something of a hub for scorpion-based drug R&D.

Mexico City-based Bioclon Institute​ exposed animals to venom extracted from scorpions (and various other poisonous species) to stimulate the production of antibodies that can be used to make anti-venoms for the treatment of bits and stings.

In contrast with Bioclon's extraction-based approach, drugs developed as a result of Valdez’s work would be easier on the local scorpion population.

She explained that although the research was prompted by “the great number of scorpions found in Colima…the idea would be to synthesise the proteins using molecular biology tools​.”

Related news

Show more

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

Shifting the Biomanufacturing Paradigm

Shifting the Biomanufacturing Paradigm

Take the Right Path Upstream with MilliporeSigma | 12-May-2020 | Technical / White Paper

The first commercial monoclonal antibody (mAb) was approved in 1986 and today, the global market is large and growing. Reports estimate the size of the...

Related suppliers

Follow us

Products

View more

Webinars